<DOC>
	<DOCNO>NCT02866916</DOCNO>
	<brief_summary>This single site , open-label , non-randomized , dose escalation phase I study design evaluate safety , tolerability Recommended Phase II Dose ( RP2D ) SXL01 , synthetic small interfere ribonucleic acid ( RNA ) target androgen receptor messenger RNA ( mRNA ) , patient metastatic castration-resistant prostate cancer . A standard method `` 3+3 '' use dose escalation . A maximum 30 patient complete dose-escalation phase study ; 12 additional patient include RP2D expansion phase .</brief_summary>
	<brief_title>Study SXL01 Patients With Metastatic Castration-Resistant Prostate Cancer ( PROSTIRNA )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms , Castration-Resistant</mesh_term>
	<criteria>1 . Males age 1880 year . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 3 . Life expectancy 3 month . 4 . Histologically confirm prostate adenocarcinoma without neuroendocrine differentiation small cell feature . 5 . Metastatic prostate cancer deem unresponsive refractory hormone therapy . 6 . Detectable metastasis bone scan , Computerized tomography ( CT ) scan Magnetic resonance imaging ( MRI ) . 7 . Surgically medically castrate , testosterone level &lt; 50 ng/dL ( &lt; 2.0 nM ) . If patient treat Luteinizing Hormone Releasing Hormone ( LHRH ) agonists ( patient undergone orchiectomy ) , therapy must initiate least 4 week prior Cycle 1 Day 1 must continue throughout study . 8 . Documented prostate cancer progression assess investigator one following : 8.1 . PSA progression define minimum two raise PSA level interval &gt; 1 week determination . The PSA value screen visit must ≥ 1 µg/l ( 1 ng/mL ) . 8.2 . Radiographic progression soft tissue disease modify RECIST criterion 1.1 bone metastasis two document new bone lesion bone scan without PSA progression . 9 . Adequate hepatic , renal , hematologic function : aspartate transaminase ( AST ) / alanine transaminase ( ALT ) ≤ 2.5 X Upper Limit Normal ( ULN ) ; Normal bilirubin ≤ 1.5 ULN case Gilbert 's syndrome ; Serum creatinine Clearance &gt; 60 mL/min CockcroftGault formula ; Hemoglobin ≥ 10 g/dL ; Absolute neutrophil count ≥ 1500/mm3 , Platelet count ≥ 100,000/mm3 . 10 . Patients must recover toxic effect prior therapy ( except alopecia ) National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) version 4.03 grade ≤1 baseline laboratory value define inclusion criterion 9 . 11 . If sexually active , willing use barrier contraception treatment phase protocol . 12 . Written inform consent locally require authorization ( e.g. , Social security France ( Health Insurance ) ) obtain patient prior perform protocolrelated procedure , include screen evaluation . 13 . Patient willing able comply protocol duration study include undergoing treatment schedule visit examination include follow . 1 . Body Mass Index ( BMI ) ≥ 30 . 2 . Evidence brain metastasis . 3 . Patient seropositive HIV and/or hepatitis B antigen positive and/or Hepatitis C antibody . 4 . Patient history autoimmune disease exception vitiligo , psoriasis control diabetes . 5 . Active suspect prior document autoimmune disease ( include inflammatory bowel disease , celiac disease , irritable bowel syndrome , Wegener 's granulomatosis Hashimoto 's thyroiditis ) . 6 . Patient history another malignancy , except follow : skin cancer ( melanoma exclude ) , previously treat cancer sign disease least 3 year . 7 . Patient concurrent infection concurrent chronic acute illness pulmonary ( asthma Chronic obstructive pulmonary disease ( COPD ) ) , cardiac ( NYHA class III IV ) hepatic disease , illness consider principal investigator constitute unwarranted high risk investigational drug administration exclude . 8 . Chronic systemic corticosteroid use within 4 week first administration SXL01 ( 2 week dose &gt; 0.5 mg/kg prednisolone ) . 9 . Treatment hormonal therapy androgen antagonist , include flutamide , bicalutamide , nilutamide , ketoconazole , diethylstilbestrol , Abiraterone , enzalutamide , within 4 week first administration exception gonadotropinreleasing hormone ( GnRH ) agonists . 10 . Patients require continuous curative anticoagulant treatment . 11 . Patients require continuous bisphosphonate denosumab treatment inclusion . Note : use bisphosphonate denosumab course study allow . 12 . Planned initiate antitumor therapy study . 13 . Radiation therapy surgery within 4 week first administration SXL01 . 14 . Mental impairment ( psychiatric illness/social situation ) may compromise ability patient give inform consent comply requirement study . 15 . Patient forfeit his/her freedom administrative legal award guardianship .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>